CLPT · XBRL financial data

ClearPoint Neuro financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CLPT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	12,829	16,299	20,551	23,955	31,390	36,971
Revenue from contracts with customers	—	—	20,551	23,955	31,390	36,971
Cost of revenue	3,709	5,008	7,020	10,341	12,268	14,279
Gross profit	9,120	11,291	13,531	13,614	19,122	22,692
Research and development	4,686	8,985	10,894	11,709	12,392	13,897
Selling, general and administrative	5,270	8,761	9,611	11,756	11,998	16,498
Operating income (loss)	(6,220)	(13,374)	(16,332)	(22,446)	(19,746)	(24,164)
Interest income	—	—	—	—	1,390	1,213
Interest expense	1,444	973	81	—	518	2,388
Other income (expense)	882	(63)	(22)	(29)	(40)	(146)
Income tax expense (benefit)	0	0	0	8	12	55
Net income (loss)	(6,782)	(14,410)	(16,435)	(22,089)	(18,914)	(25,540)
Earnings per share, basic USD per share	—	(0.69)	(0.68)	(0.90)	(0.70)	(0.90)
Earnings per share, diluted USD per share	—	(0.69)	(0.68)	(0.90)	(0.70)	(0.90)
Weighted average shares, basic thousands of shares	—	20,734	24,182	24,605	27,028	28,315
Weighted average shares, diluted thousands of shares	—	20,734	24,182	24,605	27,028	28,315

Fiscal years (CLPT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	20,099	54,109	27,615	23,140	20,104	45,923
Short-term investments	—	0	9,874	0	—	—
Accounts receivable	1,881	2,337	2,665	3,211	4,713	6,549
Inventory	3,238	4,938	9,303	7,911	6,863	8,359
Prepaid and other current assets	244	508	1,723	1,910	1,683	2,769
Total current assets	25,462	61,892	51,180	36,172	33,363	63,600
Property and equipment, net	319	539	806	1,389	2,005	2,621
Right-of-use asset	2,736	2,241	1,895	3,564	3,086	8,430
Goodwill	—	—	—	—	7,472	7,472
Total assets	29,518	65,581	55,490	42,661	39,189	97,747
Accounts payable	300	427	272	393	1,340	1,256
Total current liabilities	3,200	4,753	6,788	7,430	10,353	10,765
Lease liability, non-current	2,446	1,939	1,532	3,568	3,011	8,461
Total liabilities	27,141	16,794	18,603	21,488	13,800	69,727
Accumulated deficit	(119,522)	(133,932)	(150,367)	(172,456)	(191,370)	(216,910)
Total stockholders' equity	2,377	48,787	36,887	21,173	25,389	28,020
Total liabilities and equity	29,518	65,581	55,490	42,661	39,189	97,747
Common shares outstanding (cover page) thousands of shares	20,673	23,690	24,609	26,976	27,632	29,664

Fiscal years (CLPT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,782)	(14,410)	(16,435)	(22,089)	(18,914)	(25,540)
Stock-based compensation	1,090	2,078	4,126	6,079	6,907	8,180
Depreciation and amortization	334	159	244	626	980	814
Net cash from operating activities	(7,807)	(12,697)	(16,167)	(13,720)	(8,950)	(23,925)
Purchases of property and equipment	41	168	253	717	275	522
Net cash from investing activities	(482)	(168)	(10,736)	8,949	(275)	615
Proceeds from issuing common stock	0	46,785	0	0	16,149	3,263
Proceeds from issuing equity	376	—	—	—	—	—
Net cash from financing activities	22,692	46,875	409	296	6,189	50,179
Net change in cash	14,403	34,010	(26,494)	(4,475)	(3,036)	26,869

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
ClearPoint Neuro	46,184	12,075	(20,100)	32.1M	6.6 quarters	Q3 FY26 10-QSep 30, 2026
Outset Medical	35,005	31,635	(9,635)*	18.8M	15.3 quarters	Q2 FY26 10-QJun 30, 2026
EBR Systems	59,350	2,637	(17,194)*	75.3M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
NeuroPace	12,538	22,826	(3,903)*	34.3M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Orthopediatrics	17,141	72,661	4,506*	26.1M	—	Q3 FY26 10-QSep 30, 2026
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026
Venus Concept	4,312	13,776	(4,890)*	1.9M	0.9 quarters	Q3 FY25 10-QSep 30, 2025
Butterfly Network	122,301	32,598	(2,266)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.